Figure 2.
(A) Relative risks of conversion within 90 min in trials comparing vernakalant to comparator in patients with recent-onset atrial fibrillation. (B) Relative risks of conversion within 90 min in trials comparing vernakalant to comparator in patients with recent-onset atrial fibrillation: subgrouped according to whether participants received placebo or active drug.
